XML 58 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED AWARDS (Tables)
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity A summary of stock option activity for the year ended December 31, 2023 was as follows:
Outstanding Options
Number of OptionsWeighted Average Exercise PriceWeighted-Average Remaining Contractual Term
Intrinsic Value
(in thousands)
Balance as of December 31, 2022
39,011,116 $1.19 6.5$224,721 
Options granted
4,829,886 7.61 
Options exercised
(9,003,642)1.15 
Options canceled
(1,926,225)3.83 
Balance as of December 31, 2023
32,911,135 $1.99 5.5$91,785 
Options vested and exercisable as of December 31, 2023
26,806,933 $1.17 5.2$86,227 
Schedule of Stock Option Valuation Assumptions A summary of the weighted-average assumptions the Company utilized to record compensation expense for stock options granted during the years ended December 31, 2023 and 2021 was as follows:
December 31,
2023		December 31,
2021
Volatility
83.9 %48.4 %
Expected term (in years)5.06.6
Risk-free interest rate4.1 %1.5 %
Expected dividends— %— %
Schedule of Restricted Stock Units Activity
A summary of RSUs activity for the year ended December 31, 2023 was as follows:
Restricted Stock Units
Time-Based SharesPerformance-Based SharesTotal SharesWeighted-Average Grant-Date Fair Value
Balance as of December 31, 2022
38,570,298 2,090,140 40,660,438 $19.38 
Granted44,809,648 7,896,791 52,706,439 6.66 
Vested(19,620,735)— (19,620,735)15.62 
Cancelled/Forfeited(9,059,472)(681,106)(9,740,578)13.89 
Balance as of December 31, 2023
54,699,739 9,305,825 64,005,564 $10.90 
Schedule of Performance-Based RSUs The fair value of these performance-based RSUs was measured on the grant date, March 27, 2021, using a Monte Carlo simulation model, with the following assumptions:
Weighted average volatility60.0 %
Expected term (in years)5.0
Risk-free interest rate0.9 %
Expected dividends— %
Schedule of Stock-Based Compensation Expense
Total employee and nonemployee stock-based compensation expense for the years ended December 31, 2023, 2022 and 2021, was classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):
Year Ended December 31,
202320222021
Cost of revenue$3,590 $41,753 $8,737 
Research and development137,703 151,549 137,303 
Selling, general and administrative117,433 230,198 370,717 
Restructuring charges
(1,443)— — 
Total$257,283 $423,500 $516,757